Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.
暂无分享,去创建一个
Wei Zhao | Jun Wang | Lap Ho | G. Pasinetti | L. Ho | Jun Wang | Linghong Chen | C. Rosendorff | Wei Zhao | Giulio Maria Pasinetti | Zhong Zhao | Nelson Humala | Linghong Chen | Clive Rosendorff | Xianjuan Qian | Ilana Seror | Sadie Bartholomew | Zhong Zhao | N. Humala | X. Qian | I. Seror | S. Bartholomew
[1] B. Hyman,et al. Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[2] Singer Rb. Stroke in the elderly treated for systolic hypertension (SHEP) part II--mortality. , 1991 .
[3] P. Zandi,et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. , 2006, Archives of neurology.
[4] M. Prince,et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults , 1996, BMJ.
[5] R. Morris. Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.
[6] D. Morgan. Mechanisms of Aβ Plaque Clearance following Passive Aβ Immunization , 2006, Neurodegenerative Diseases.
[7] T. Saibara,et al. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. , 2003, The Journal of endocrinology.
[8] B. Winblad,et al. Low Blood Pressure and Incidence of Dementia in a Very Old Sample: Dependent on Initial Cognition , 1999, Journal of the American Geriatrics Society.
[9] W. K. Cullen,et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.
[10] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[11] D. Selkoe,et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.
[12] W. Klein. Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets , 2002, Neurochemistry International.
[13] P. Hof,et al. The FASEB Journal express article 10.1096/fj.05-4359fje. Published online September 26, 2005. , 2022 .
[14] E. Leof,et al. The FASEB Journal • Research Communication Imatinib mesylate blocks a non-Smad TGF- � pathway and reduces renal fibrogenesis in vivo , 2022 .
[15] T. Oltersdorf,et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.
[16] P. Hof,et al. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease , 2004, Acta Neuropathologica.
[17] D. Morgan. Mechanisms of A beta plaque clearance following passive A beta immunization. , 2005, Neuro-degenerative diseases.
[18] D. Rodríguez‐Puyol,et al. Crosstalk Between Mesangial and Endothelial Cells: Angiotensin II Down-Regulates Endothelin-Converting Enzyme 1 , 2005, Cellular Physiology and Biochemistry.
[19] S. Estus,et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. , 1992, Science.
[20] A. Hofman,et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization , 2004, Journal of hypertension.
[21] D. Westaway,et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.
[22] A. Hofman,et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.
[23] T. Tong,et al. Expression of the Leo1‐like domain of replicative senescence down‐regulated Leo1‐like (RDL) protein promotes senescence of 2BS fibroblasts , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] J. Birks,et al. Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.
[25] P. Hof,et al. Caloric restriction attenuates β‐amyloid neuropathology in a mouse model of Alzheimer's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] Patrick R Hof,et al. Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] G. Pasinetti,et al. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. , 2002, The Journal of pharmacology and experimental therapeutics.
[28] Mark Bowlby,et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[29] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[30] S. Yamamoto,et al. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models. , 1997, Arzneimittel-Forschung.
[31] D. Selkoe,et al. Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.
[32] W. K. Cullen,et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. , 2005, Nature medicine.
[33] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[34] J. Buxbaum,et al. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease , 2007, Neurobiology of Aging.
[35] Jaakko Tuomilehto,et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .
[36] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[37] P. Matsudaira,et al. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[38] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[39] P. S. St George-Hyslop,et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. , 2002, Nature medicine.
[40] A. Hofman,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.
[41] K. Tanzawa,et al. Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. , 1995, The Biochemical journal.
[42] D. Westaway,et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.
[43] Mikio Shoji,et al. Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.
[44] L. Hersh,et al. Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.